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ABSTRACTSBackground:MicroRNAs have potential as urinary biomarkers for the non-
invasive identiﬁcation of new and recurrent bladder cancer. Unprocessed
RNA rapidly degrades and the standard procedure for stabilising RNA
cannot be performed in outpatient clinics. We compared a novel method of
urinary sediment ﬁltration and RNA stabilisation to the gold standard.
Method: Pooled normal urine samples were divided into 30 mL aliquots
and either immediately ﬁltered and stored in lysis buffer at 20C, or stored
at 20C, and either ﬁltered or centrifuged prior to disrupting the cells in
lysis buffer. Samples were between baseline and 48 hrs or 7 days then
transferred to -80C. RNAwas extracted and reverse transcribed. MicroRNA
and mRNA transcripts were quantiﬁed by real-time PCR.
Results: MicroRNA copies decreased by >50% within 48hr in ﬁltered and
centrifuged samples stored at 20C. Filtration was superior to
centrifugation and RNA copy was maintained in the stabilising buffer for
48hr at 20C. Time course experiments extended to 7d this showed no
signiﬁcant alteration in copies for microRNA or mRNA.
Conclusion: The urine ﬁlter method is superior to centrifugation and can
incorporate a lysis and stabilisation step as a simple, reproducible
approach to obtaining RNA in an outpatient clinic.0189 IS FOLLOW-UP REQUIRED FOR UNCOMPLICATED DISTAL
URETERIC STONES <6 MM?
Vimoshan Arumuham, Sheel Mehta, Stefanos Almpanis, David Nicol, Leye
Ajayi. Royal Free Hampstead NHS Trust, London, UK
Background: At our institution all patients with ureteric colic presenting
through A&E are followed up in Stone Clinic. To assess the strain on limited
resources, we performed a retrospective analysis to ascertain the value of
follow-up in patients with uncomplicated distal ureteric stones <6mm in
size.
Patients & Methods: Of the 320 patients who had a CT-KUB over one year,
180 patients had a ureteric calculus. Presentations that were managed
conservatively either after a short admission (n¼80) or directly discharged
from A&E (n¼77) were included. We obtained stone-size and position,
hydronephrosis, concurrent stone burden, medical expulsive therapy, re-
presentation rates and follow-up attendance.
Results: 157/180 were managed conservatively and had follow-up
arranged at discharge.129/157(82%) patients had a solitary stone<6mm in
the ureter. 110/157(70%) had a distal ureteric stone. 90/157 (57%) were
ﬁrst-time stone formers. 80/157 (51%) patients did not attend outpatient
clinic. Patients were contacted and 69/80 DNA as they were asymptomatic
with 11 lost to follow-up. Re-admission was more likely in previous stone
formers or patients with concurrent stone burden elsewhere in the urinary
tract (p<0.05).
Conclusion: First-time stone formers presenting to A&E with uncompli-
cated solitary distal ureteric calculi<6mmmaynot routinely need follow-up.0193 THERAPEUTIC CHALLENGES IN MANAGEMENT OF VULVAL
INTRAEPITHELIAL NEOPLASIA (VIN): CONSERVATIVE VS RADICAL
TREATMENT OPTIONS
Jessica Hui Cheah Lim 1, Farhad Alexander Sefre 1, Muhammad Waqas
Ahmad Mangat 1, Grace Hui Chin Lim 2. 1Department of Gynaeoncology
of Glasgow Royal Inﬁrmary, Glasgow, UK; 1University of Glasgow,
Glasgow, UK
Background: The incidence of Vulval intraepithelial neoplasia (VIN) is
rising in young patients. The management of VIN is not well established.
Objective: To compare the efﬁcacy of radical vulvectomy, wide local exci-
sion (WLE), CO2 laser ablation and various medical therapies in treatment
of VIN.
Methods: All the literature in Pubmed and Medline were examined. 3075
patients from retrospective and prospective trials from 1968 to March
2009 were analysed. Recurrence rates, disease free intervals, advantages
and disadvantages of each treatment were examined.
Results: Radical vulvectomy was best in reducing VIN recurrences (mean
rate 17.6%). The combined technique (WLE+laser ablation) was next best
(mean recurrence 25%), followed by WLE (26%) and laser ablation (30%).
The most effective medical therapy was imiquimod (short-term mean
recurrence 29.5%), followed by photodynamic therapy, PDT (43.8%).Discussion: Vulvectomy is largely abandoned due to severe psychosexual
sequels. The current standard practice is WLE. Laser ablation is more
cosmetically acceptable and should be considered on younger women.
Imiquimod and PDT are effective in short- term, but further prospective
studies needed to establish long-term efﬁcacy.
Conclusion: There is no single best treatment. Speciﬁc treatments should
be tailored to individual patients depending on nature of VIN, clinician's
experience and patients' preference.
0198 ACCESS TO NOVEL CANCER SURGERY: IS IT EQUITABLE?
Jonathan Clarke 1, Sophie Holmes 1, Yoryos Lyratzopoulos 2. 1 School of
Clinical Medicine, University of Cambridge, Cambridge, UK; 1 Institute of
Public Health, University of Cambridge, Cambridge, UK
Background: A better understanding of factors inﬂuencing the uptake and
dissemination of new surgical procedures is essential in order to reduce
variation and improve quality of care. Purpose: To use Hospital Episode
Statistics to monitor regional variation in access to novel surgical proce-
dures for cancer therapy.
Methods:We focused on the 12 cancer-related new procedures for which
NICE has produced guidance and which directly match procedure codes in
the OPCS-4 interventional procedures classiﬁcation system. We then used
Hospital Episode Statistics (HES) data to analyse relevant healthcare
activity from 2000 to 2009.
Results: Procedure use is driven initially by ‘early implementer' hospitals
but diffuses over time. Regional variation is associatedwith the presence of
innovator hospitals, without a systematic under- or over-utilisation
between different English regions.
Conclusion: The diffusion of new interventional procedures is led by
innovator hospitals but appears to follow no other systematic geographical
pattern. In their infancy, surgical procedures remain strongly restricted to
the regions surrounding 'innovator hospitals'. A patient's access to a novel
interventional procedure for cancer treatment is therefore determined by
their region of residence. Monitoring of procedure use is constrained by
the lack of speciﬁc codes for new procedures, and we strongly support
initiatives for the timely creation of such codes.0200 IS THERE A ROLE FOR ABDOMINAL RADIOGRAPHS IN THE INITIAL
ASSESSMENT OF PATIENTS PRESENTING WITH NON-TRAUMATIC
ABDOMINAL PAIN?
Venkitaraman Sathya, Kunal Shetty, Mac Armstrong. Plymouth Hospitals
NHS Trust, Plymouth, Devon, UK
Aim: Abdominal radiographs (AXR) are indiscriminately requested despite
it having a low diagnostic yield. The aim was to determine the proportion
of patients presenting to the Surgical Admissions Unit (SAU) with non-
traumatic abdominal pain who underwent AXR with abnormal ﬁndings at
the time of initial assessment.
Methods: The audit was for a period of two months where data was
collected prospectively and all AXRs were reported by a single consultant
radiologist.
Results: A total of 515 patients presented to SAU with non-traumatic
abdominal pain during the study period and 32.4% of them underwent an
AXR on admission as part of the initial assessment. Our analysis showed
that a higher percentage (54.1%) of elderly patients underwent an AXR.
Only 16.8% of all AXRs detected abnormalities while the rest were either
reported as normal or had non-speciﬁc ﬁndings.
Conclusion:Weconclude thatAXRshouldnot beusedas a routine screening
tool for patients presenting with the above as it has a low diagnostic yield.
Other modalities such as ultrasonography scans or computerised tomog-
raphy scans as the primary imaging modality must be considered if indi-
cated. Better education and awareness among junior doctors could further
reduce the proportion of patients undergoing unnecessary AXR.0203 BREAST CANCER AND ATYPICAL HYPERPLASIA IN REDUCTION
MAMMOPLASTY SPECIMENS: 10-YEAR EXPERIENCE
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